Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvocidib in R/R AML Post-Venetoclax
NCT03969420Phase 2Terminated
- Sponsor
- Sumitomo Pharma America
- Start
- Jan 2020
- Primary completion
- Apr 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alvocidib in acute myeloid leukemia (AML), sponsored by Sumitomo Pharma America. Primary endpoint: Combined Complete Remission at 3 months. Started Jan 2020; status: terminated.
02
Drugs
alvocidib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03969420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969420.